Fulcrum Therapeutics reported its financial results for the fourth quarter and full year 2024, ending 2024 with $241.0 million in cash, cash equivalents, and marketable securities. The company maintains a projected cash runway into at least 2027, providing financial stability for its operations.
For the full year 2024, Fulcrum reported $80.0 million in collaboration revenue, a significant increase of $77.2 million compared to 2023, primarily due to an upfront Sanofi payment. This led to a net income of $6.843 million for the full year 2024, a substantial improvement from a net loss of $72.579 million in 2023.
In the fourth quarter of 2024, the company recorded a net loss of $25.126 million, compared to a net loss of $27.440 million in Q4 2023. Progress was noted in the Phase 1b PIONEER trial of pociredir for sickle cell disease, with the 10th patient enrolled in the 12 mg dose cohort, and clinical data from this cohort expected in mid-2025, with data from the 20 mg dose cohort anticipated by the end of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.